Aquestive Therapeutics (AQST) Stock Price, News & Analysis

Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a pharmaceutical company focused on advancing medicines through proprietary drug delivery technologies. According to company disclosures, Aquestive develops orally administered products designed to deliver complex molecules and provide alternatives to invasive and inconvenient standard-of-care therapies. The company operates in the medicinal and botanical manufacturing industry within the broader manufacturing sector.

Aquestive states that it has four commercialized products that are marketed by its licensees in the United States and internationally, and that it is the exclusive manufacturer of these licensed products. In addition to its own proprietary pipeline, the company collaborates with other pharmaceutical companies to bring new molecules to market using its proprietary technologies, including its PharmFilm® platform. Company materials describe PharmFilm as a core technology used in multiple licensed and pipeline products.

Business model and operations

Based on the company’s public descriptions, Aquestive’s business model combines internal product development with manufacturing and licensing arrangements. The company develops its own proprietary product candidates and also manufactures and supplies film-based and related products for partners under license and supply agreements. Aquestive notes that its manufacturing business includes products such as Suboxone® Sublingual Film for Indivior, Sympazan® (clobazam) Oral Film for Assertio Holdings, Inc. in the U.S., and Ondif® (ondansetron) Oral Film for Hypera Pharma in Brazil. It also indicates that sales of royalty-based products, including Sympazan and Azstarys® (serdexmethylphenidate and dexmethylphenidate), contribute to its revenue.

The company describes itself as a U.S.-based manufacturer with intellectual property domiciled in the United States. Public statements indicate that Aquestive’s supply chain has remained largely unaffected in the near term by implemented and proposed government tariffs, which the company associates with reliability and stability in production and global distribution.

Key proprietary pipeline programs

A major focus of Aquestive’s current pipeline is the development of epinephrine prodrug products for severe allergic reactions and dermatologic conditions. Company communications repeatedly highlight a late-stage proprietary product candidate and an early-stage topical program:

• Anaphylm™ (dibutepinephrine) Sublingual Film (also described as epinephrine sublingual film): Aquestive identifies Anaphylm as a polymer matrix-based epinephrine prodrug product candidate in sublingual film form. The company states that Anaphylm is similar in size to a postage stamp, begins to dissolve on contact, does not require water or swallowing, and is packaged in a thin, credit-card-sized primary package designed to be carried in a pocket, phone, or wallet and to withstand exposure to rain and sunlight. Public materials describe Anaphylm as a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis. The company notes that the Anaphylm trade name for AQST‑109 has been conditionally approved by the U.S. Food and Drug Administration (FDA), with final approval of the proprietary name conditioned on FDA approval of the product candidate itself.
• AdrenaVerse™ epinephrine prodrug platform: Aquestive refers to Anaphylm as part of its AdrenaVerse™ platform, which it describes as a library of epinephrine prodrug product candidates intended to control absorption and conversion rates across different dosage forms and delivery sites. Company disclosures indicate that Aquestive is committed to developing additional products from this platform.
• AQST‑108 (epinephrine) Topical Gel: Aquestive describes AQST‑108 as a topically delivered adrenergic agonist prodrug gel product candidate, based on the AdrenaVerse platform, in development for various possible dermatologic conditions, including alopecia areata. The company has reported completing a first-in-human study that measured epinephrine remaining on the skin and in circulation over time after gel application.

Regulatory and clinical context for Anaphylm

Aquestive has publicly detailed an extensive clinical and regulatory program for Anaphylm. According to company press releases, the New Drug Application (NDA) for Anaphylm is supported by a clinical development program consisting of eleven independent clinical studies with approximately 967 total administrations across 411 subjects, including both single-dose and repeat-dose exposures. The company reports that these studies demonstrated a pharmacokinetic profile comparable to leading epinephrine auto-injectors and that Anaphylm was generally well tolerated with a safety profile similar to epinephrine.

The company has also described a first-of-its-kind oral allergy syndrome study designed to evaluate Anaphylm’s performance in a real-world, allergen-induced setting. Aquestive states that the FDA has informed the company that an advisory committee meeting is not required for the Anaphylm NDA and that the agency’s review remains ongoing. In a later update, the company disclosed that the FDA identified deficiencies in the NDA that preclude labeling discussions at that time, while also indicating that the review of the application is ongoing and that no final decision has been made.

Beyond the United States, Aquestive has reported regulatory engagement in Canada, Europe, and the United Kingdom for Anaphylm. The company has stated that it expects to submit a New Drug Submission to Health Canada and a marketing authorization application in Europe, and that it has received feedback from the European Medicines Agency indicating that no further clinical trials are needed prior to regulatory submission. Aquestive characterizes these markets as important opportunities to expand access to its non-invasive epinephrine therapy, subject to regulatory approvals.

Libervant® and seizure rescue therapies

Aquestive has also developed Libervant® (diazepam) Buccal Film, which it describes as a buccally administered film formulation of diazepam for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (seizure clusters or acute repetitive seizures) in epilepsy patients. Company materials state that Libervant was developed as an alternative to device-based rescue therapies such as rectal gels and nasal sprays. Aquestive explains that Libervant has received tentative approval in the United States due to orphan drug market exclusivity held by another company’s intranasal spray product, and that U.S. market access is currently subject to the expiration of that exclusivity, which the company associates with a future date. The company emphasizes its belief that expanding patient access to non-invasive seizure rescue therapies is important and that it remains committed to making Libervant available when full approval for U.S. market access is granted.

Intellectual property and technology

Aquestive has highlighted its intellectual property strategy around Anaphylm and its epinephrine prodrug technologies. The company has announced the issuance of additional U.S. patents related to enhanced delivery epinephrine compositions and epinephrine prodrug compositions, with claims that cover formulations designed for oral mucosal absorption via film. Public statements indicate that these composition-of-matter patents are expected to provide protection into the next decade, subject to any extensions.

Across its communications, Aquestive consistently points to its proprietary technologies, including PharmFilm® and AdrenaVerse™, and its experience in drug development, manufacturing, and commercialization as core capabilities. The company positions these capabilities as the basis for both its internal pipeline and its collaborations with partner companies.

Capital structure and agreements

In addition to product and pipeline information, Aquestive’s SEC filings describe financing arrangements linked to its product candidates. For example, the company has entered into a purchase and sale agreement with funds managed by RTW Investments LP, under which the purchaser is entitled to tiered revenue share payments on U.S. net sales of Anaphylm, subject to conditions including FDA approval of Anaphylm and refinancing of existing senior secured notes. The agreement includes covenants that affect the company’s ability to incur indebtedness, with certain restrictions eliminated after the purchaser achieves a specified return. Aquestive also discloses obligations under a separate royalty rights agreement that require payments of a portion of revenues to third parties.

These arrangements, as described by the company, are intended to provide capital to support regulatory, clinical, and commercial activities for Anaphylm and other product candidates, while creating future payment obligations tied to product sales and revenue thresholds.

Stock information and regulatory reporting

Aquestive Therapeutics, Inc. reports that its common stock trades on the Nasdaq Global Market under the ticker symbol AQST. The company files periodic and current reports with the U.S. Securities and Exchange Commission, including Form 8‑K filings that disclose material events such as financial results, investor presentations, patent developments, and financing transactions. These filings provide additional detail on the company’s operations, financial condition, risk factors, and strategic priorities.